MLYSMineralys Therapeutics, Inc.

HealthcareUSD
$25.88

The financials

Mineralys Therapeutics, Inc. by the numbers

Mineralys Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$246M−$47Mn/a
Net income−$241M−$43Mn/a
Diluted EPS−$2.85−$0.66n/a

Biotechnology

Ranks #110 of 145 by Smart Score

Compare peers
NRIX+16%
Nurix Therapeutics, Inc.
PHVS+0.03%
Pharvaris N.V.
BHVN+2.5%
Biohaven Ltd.
SLBT+12%
SL Science Holding Limited
MRVI+6.2%
Maravai LifeSciences Holdings, Inc.
AUPH-5.7%
Aurinia Pharmaceuticals Inc.